Hanmi Pharm. Partners with Lilly for Innovative Sonefpeglutide Development and Licensing Agreement

Hanmi Pharm and Eli Lilly's Strategic Licensing Agreement for Sonefpeglutide

In a significant move in the biopharmaceutical sector, Hanmi Pharm. Co., Ltd., based in Seoul, South Korea, has announced a licensing agreement with Eli Lilly and Company, one of the foremost innovators in the global healthcare landscape. The agreement focuses on the development, manufacturing, and commercialization of Hanmi's promising biologic drug candidate, sonefpeglutide (LAPSGLP-2 analog).

Sonefpeglutide leverages Hanmi's cutting-edge LAPSCOVERY™ platform technology, which is designed for the creation of long-acting biologics, providing necessary advances for an effective treatment option in several medical conditions. Hanmi’s previous successes with the LAPSCOVERY platform have led to FDA approval for another biologic product, showcasing the platform’s substantial potential in addressing major health issues.

The drug’s formulation is rooted in the biological functionalities of glucagon-like peptide 2 (GLP-2), a critical hormone that plays a significant role in promoting intestinal growth and reducing inflammation. The ongoing research has consistently demonstrated the drug’s capability in protecting and regenerating the intestinal mucosa, suggesting promising applications for patients suffering from various gastrointestinal disorders.

Currently, Hanmi is conducting a global Phase 2 clinical trial focusing on short bowel syndrome (SBS), aiming to bring forth a viable treatment for this challenging condition. Meanwhile, Eli Lilly will explore further clinical research opportunities for sonefpeglutide based on Hanmi's comprehensive preclinical and clinical data. This collaborative effort is poised to enhance the therapeutic landscape for several indications, illustrating the broad potential of the compound.

Juhyun Lim, Vice Chairman of Hanmi, expressed enthusiasm over the partnership, stating, "The collaboration with Lilly underscores the potential recognized for sonefpeglutide by one of the most innovative companies globally. Hanmi remains committed to advancing inventive drug development, aligned with our mission of 'Respect for People and Value Creation.'"

The financial details of this agreement are also noteworthy. Hanmi will receive an upfront payment of $75 million, with additional potential earnings of up to $1.185 billion tied to the achieving of various clinical development, regulatory approval, and commercialization milestones. Moreover, once the product launches, Hanmi will earn royalties, providing a revenue stream that could further support its innovative research initiatives.

Hanmi Pharm. remains firmly committed to addressing significant unmet medical needs, focusing on obesity/metabolism, oncology, and rare diseases. With a strong emphasis on research and development, the company utilizes its proprietary technologies to create effective solutions. Collaborative partnerships like the one with Lilly exemplify Hanmi's strategy to enhance its capabilities and reach in the biopharmaceutical field, ensuring that innovative therapies are developed for the benefit of patients worldwide.

With this strategic licensing agreement, both Hanmi and Lilly are set to make impactful strides in the biopharmaceutical landscape, potentially reaching new horizons in the treatment of critical health issues. As clinical trials move forward, the pharmaceutical community and patients globally will be keenly watching the progress of sonefpeglutide, anxiously anticipating the new developments that emerge from this partnership.